Author: Oannes Biotech

This author has written 64 articles
Read more about the article Major Milestone: FDA Grants Approval to Vertex and CRISPR Therapeutics for CASGEVY™ in the Treatment of Sickle Cell Disease

Major Milestone: FDA Grants Approval to Vertex and CRISPR Therapeutics for CASGEVY™ in the Treatment of Sickle Cell Disease

Groundbreaking Gene-Editing Therapy Receives Green Light, Signaling a New Era in Sickle Cell Treatment Date: 12 December 2023 Introduction: In a landmark decision, the U.S. Food and Drug Administration (FDA)…

Continue ReadingMajor Milestone: FDA Grants Approval to Vertex and CRISPR Therapeutics for CASGEVY™ in the Treatment of Sickle Cell Disease
Read more about the article Revolutionizing Treatment: UK Grants Authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for Groundbreaking CRISPR/Cas9 Gene-Edited Therapy

Revolutionizing Treatment: UK Grants Authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for Groundbreaking CRISPR/Cas9 Gene-Edited Therapy

MHRA Approves CASGEVY™ for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, Marking a Milestone in Precision Medicine Date: 7 December 2023 Introduction: In a historic move that signals a new…

Continue ReadingRevolutionizing Treatment: UK Grants Authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for Groundbreaking CRISPR/Cas9 Gene-Edited Therapy